The Ohio State University Comprehensive Cancer Center (OSUCCC) is currently in its 29th year as an NCI-designated CCC and is now requesting continued federal support for the next five years. The OSUCCC named its 4th Director, Michael A. Caligiuri, M.D. in July, 2003 while retaining the former Center Director, Clara D. Bloomfield, M.D., as a Senior Advisor to the OSUCCC. The overall goal remains to reduce cancer morbidity and mortality through continued basic, translational and clinical research. The 183 OSUCCC members are currently served by 13 shared resources and are distributed among 6 Research Programs: Cancer Control, Experimental Therapeutics, Immunology, Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention and Viral Oncogenesis. Since the last competitive renewal, the OSUCCC has shown significant growth as demonstrated by: 1) the recruitment of more than 90 new cancer research faculty to OSU; 2) more than a 230% increase in patient accrual to investigator-initiated trials; 3) the addition of 6 new shared resources at an institutional investment of over $10.8 M; 4) a 144% increase in total NCI funding and a 65% increase in peer-reviewed funding. The OSUCCC has also seen tremendous growth in institutional commitment since 1999 as demonstrated by: 1) a new formal role for the OSUCCC Director within OSU, providing complete oversight of the University-wide cancer funding initiatives, opportunities and cancer grant submissions; 2) A seat on the eight-member Medical Center Executive Committee which meets every week with the Senior VP of Health Sciences to plan and evaluate the entire Health System's direction (cancer is the only discipline represented on this Committee); 3) a written commitment for the expansion of the Cancer Program facilities that will result in more than a four-fold increase over the current square footage under control of the OSUCCC Director at a cost of approximately $350 M; 4) interim laboratory and office space for recruitment until the new facility is constructed; 5) an additional $7.0 M of cash annually from OSU for research and infrastructure expansion; and 6) twenty senior faculty slots under the control of the OSUCCC Director, each provided with $100,000 of guaranteed salary in perpetuity. With these new resource commitments in place, the OSUCCC is poised for significant growth and expansion in the next 5 years.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Colombo, Mara; Lòpez-Perolio, Irene; Meeks, Huong D et al. (2018) The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. Hum Mutat 39:729-741
Hendricks, William P D; Zismann, Victoria; Sivaprakasam, Karthigayini et al. (2018) Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet 14:e1007589
Gardner, Heather L; Rippy, Sarah B; Bear, Misty D et al. (2018) Phase I/II evaluation of RV1001, a novel PI3K? inhibitor, in spontaneous canine lymphoma. PLoS One 13:e0195357
Barnhouse, Victoria R; Weist, Jessica L; Shukla, Vasudha C et al. (2018) Myoferlin regulates epithelial cancer cell plasticity and migration through autocrine TGF-?1 signaling. Oncotarget 9:19209-19222
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Di Marcantonio, Daniela; Martinez, Esteban; Sidoli, Simone et al. (2018) Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res 24:608-618
Pettit, Cory; Webb, Amy; Walston, Steve et al. (2018) MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma. Oncotarget 9:28951-28964
Miller, Eric D; Fisher, James L; Haglund, Karl E et al. (2018) Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Radiat Oncol 13:196
Fenn, J Daniel; Johnson, Christopher M; Peng, Juan et al. (2018) Kymograph analysis with high temporal resolution reveals new features of neurofilament transport kinetics. Cytoskeleton (Hoboken) 75:22-41
Mathew, Nimitha R; Baumgartner, Francis; Braun, Lukas et al. (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24:282-291

Showing the most recent 10 out of 2602 publications